Acarbose and Secondary Prevention After Coronary Stenting
The purpose of this study is to determine whether the intervention for newly diagnosed abnormal glucose tolerance after coronary stenting will improve the long-term clinical outcome...
Brief Summary
Official Title: “Effects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance With Coronary Artery Disease (ALERT Study)”
The purpose of this study is to determine whether the intervention for newly diagnosed abnormal glucose tolerance after coronary stenting will improve the long-term clinical outcome.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Detailed Clinical Trial Description
Recent studies have demonstrated that newly diagnosed abnormal glucose tolerance (AGT; diabetes mellitus and impaired glucose tolerance) are common among the patients with ischemic heart disease. Several large cohort studies indicate that people with prediabetic conditions, such as impaired glucose tolerance, have a raised risk of future cardiovascular disease. Intervention with acarbose can prevent myocardial infarction and cardiovascular disease in type 2 diabetic and IGT patients. However, the effect of acarbose to secondary prevention of myocardial infarction or cardiovascular events in patients with newly diagnosed AGT after coronary stenting remains unclear. The purpose of the present study is to determine whether the intervention to such abnormalities after coronary stenting will improve the long-term clinical outcome. This is a opened, randomized study to compare acarbose versus a standard lifestyle modification. Patients will have a 1:1 chance of receiving acarbose versus the standard lifestyle modification. There is some research evidence that suggests acarbose may improve clinical outcome in patients with type 2 diabetes and in IGT patients.
Intervention(s) in this Clinical Trial
- Drug: Acarbose
Outcome Measures for this Clinical Trial
Primary Measures
- Cardiovascular event free survival time
Secondary Measures
- Conversion of abnormal glucose tolerance to type 2 diabetes
- All causes of death
- Occurrence of every cardiovascular event
- Occurrence of in-stent restenosis
- Change in fasting, 2-hour blood glucose and insulin level
- Change in homeostasis model assessment of insulin resistance
- Change in hemoglobin A1c (HbA1c)
- Change in lipid profile
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Within 8 weeks since implantation of coronary artery stents for stable angina pectoris or acute coronary syndrome.
- Abnormal glucose tolerance according to a 75 g oral glucose tolerance test (OGTT).
- HbA1c is less than 6.5%.
- Age is between 20 and 75 years (at time of consent).
- Patients who can give informed consent themselves in writing.
Exclusion Criteria:
- Patients with abnormal glucose tolerance caused by other organic disorders such as pancreatitis, hemochromatosis, post pancreatectomy, hyperthyroidism, Cushing syndrome, Prader-Willi syndrome, etc.
- Patients with planned angioplasty.
- Patients with uncontrollable congestive heart failure.
- Less than 6 months since last episode of cerebral infarction.
- Patients who have received medication for diabetes mellitus before.
- AST (GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L.
- Creatinine exceeding 2 mg/dl.
- Patients with a history of ileus or less than 6 months since celiotomy.
- Pregnant women or those who plan to become pregnant, or are in the lactation period.
- Habitual drinker (more than 100 ml/day of alcohol).
- Patients with a history of gastrectomy.
- Patients for whom it is impossible to follow up for 5 years.
- Any other reason that the clinical supervisors or clinical researchers may have for considering a case unsuitable for the study.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 20 Years
Maximum Age for this Clinical Trial: 75 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Translational Research Informatics Center, Kobe, Hyogo, Japan Other
Overall Clinical Trial Officials and Contacts
Koichi Tamita, MD. Principal Investigator Division of Cardiology, Kobe General Hospital
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00221156
Study ID Number: BRI_CAD_04-02
ClinicalTrials.gov Identifier: NCT00221156
Health Authority: Japan: Ministry of Health, Labor and Welfare
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00221156
